These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 18698192)

  • 1. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome.
    Berry-Kravis E; Sumis A; Hervey C; Nelson M; Porges SW; Weng N; Weiler IJ; Greenough WT
    J Dev Behav Pediatr; 2008 Aug; 29(4):293-302. PubMed ID: 18698192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label riluzole in fragile X syndrome.
    Erickson CA; Weng N; Weiler IJ; Greenough WT; Stigler KA; Wink LK; McDougle CJ
    Brain Res; 2011 Mar; 1380():264-70. PubMed ID: 21059347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-label add-on treatment trial of minocycline in fragile X syndrome.
    Paribello C; Tao L; Folino A; Berry-Kravis E; Tranfaglia M; Ethell IM; Ethell DW
    BMC Neurol; 2010 Oct; 10():91. PubMed ID: 20937127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.
    Jacquemont S; Curie A; des Portes V; Torrioli MG; Berry-Kravis E; Hagerman RJ; Ramos FJ; Cornish K; He Y; Paulding C; Neri G; Chen F; Hadjikhani N; Martinet D; Meyer J; Beckmann JS; Delange K; Brun A; Bussy G; Gasparini F; Hilse T; Floesser A; Branson J; Bilbe G; Johns D; Gomez-Mancilla B
    Sci Transl Med; 2011 Jan; 3(64):64ra1. PubMed ID: 21209411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated thyrotropin in bipolar youths prescribed both lithium and divalproex sodium.
    Gracious BL; Findling RL; Seman C; Youngstrom EA; Demeter CA; Calabrese JR
    J Am Acad Child Adolesc Psychiatry; 2004 Feb; 43(2):215-20. PubMed ID: 14726729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.
    Heussler H; Cohen J; Silove N; Tich N; Bonn-Miller MO; Du W; O'Neill C; Sebree T
    J Neurodev Disord; 2019 Aug; 11(1):16. PubMed ID: 31370779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.
    Berry-Kravis EM; Hessl D; Rathmell B; Zarevics P; Cherubini M; Walton-Bowen K; Mu Y; Nguyen DV; Gonzalez-Heydrich J; Wang PP; Carpenter RL; Bear MF; Hagerman RJ
    Sci Transl Med; 2012 Sep; 4(152):152ra127. PubMed ID: 22993294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome.
    Wang X; Snape M; Klann E; Stone JG; Singh A; Petersen RB; Castellani RJ; Casadesus G; Smith MA; Zhu X
    J Neurochem; 2012 May; 121(4):672-9. PubMed ID: 22393900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study.
    Çaku A; Pellerin D; Bouvier P; Riou E; Corbin F
    Am J Med Genet A; 2014 Nov; 164A(11):2834-42. PubMed ID: 25258112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome.
    McBride SM; Choi CH; Wang Y; Liebelt D; Braunstein E; Ferreiro D; Sehgal A; Siwicki KK; Dockendorff TC; Nguyen HT; McDonald TV; Jongens TA
    Neuron; 2005 Mar; 45(5):753-64. PubMed ID: 15748850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential translation and fragile X syndrome.
    Vanderklish PW; Edelman GM
    Genes Brain Behav; 2005 Aug; 4(6):360-84. PubMed ID: 16098135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of mavoglurant and its potential for the treatment of fragile X syndrome.
    Gomez-Mancilla B; Berry-Kravis E; Hagerman R; von Raison F; Apostol G; Ufer M; Gasparini F; Jacquemont S
    Expert Opin Investig Drugs; 2014 Jan; 23(1):125-34. PubMed ID: 24251408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arbaclofen in fragile X syndrome: results of phase 3 trials.
    Berry-Kravis E; Hagerman R; Visootsak J; Budimirovic D; Kaufmann WE; Cherubini M; Zarevics P; Walton-Bowen K; Wang P; Bear MF; Carpenter RL
    J Neurodev Disord; 2017; 9():3. PubMed ID: 28616094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Social behavior phenotypes in fragile X syndrome, autism, and the Fmr1 knockout mouse: theoretical comment on McNaughton et al. (2008).
    Brodkin ES
    Behav Neurosci; 2008 Apr; 122(2):483-9. PubMed ID: 18410188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
    Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
    J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.
    Berry-Kravis E; Des Portes V; Hagerman R; Jacquemont S; Charles P; Visootsak J; Brinkman M; Rerat K; Koumaras B; Zhu L; Barth GM; Jaecklin T; Apostol G; von Raison F
    Sci Transl Med; 2016 Jan; 8(321):321ra5. PubMed ID: 26764156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial.
    Berry-Kravis E; Krause SE; Block SS; Guter S; Wuu J; Leurgans S; Decle P; Potanos K; Cook E; Salt J; Maino D; Weinberg D; Lara R; Jardini T; Cogswell J; Johnson SA; Hagerman R
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):525-40. PubMed ID: 17069542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in fragile X: a model for autism and neurodegeneration.
    Hagerman RJ; Ono MY; Hagerman PJ
    Curr Opin Psychiatry; 2005 Sep; 18(5):490-6. PubMed ID: 16639106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragile X mental retardation protein is required for chemically-induced long-term potentiation of the hippocampus in adult mice.
    Shang Y; Wang H; Mercaldo V; Li X; Chen T; Zhuo M
    J Neurochem; 2009 Nov; 111(3):635-46. PubMed ID: 19659572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, placebo-controlled crossover study of folinic acid (Leucovorin for the treatment of fragile X syndrome.
    Strom CM; Brusca RM; Pizzi WJ
    Am J Med Genet; 1992 Nov; 44(5):676-82. PubMed ID: 1481832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.